Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinoma

Int J Mol Med. 2000 Jan;5(1):33-41. doi: 10.3892/ijmm.5.1.33.

Abstract

The Hep3B cell line analyzed in the present study is a widely used in vitro model in studies characterizing pathogenetic, functional, and therapeutic aspects of human hepatocellular carcinoma (HCC). Here we have determined the chromosomal composition using a combination of cytogenetic techniques. In agreement with the original description for this cell line, Hep3B was found to have a hypotriploid chromosome content carrying 59-63 chromosomes and no cytogenetic differences were demonstrated between early and late passages suggesting that this cell line has remained stable after repeated subculturing. Mutations and alterations of the IGF-axis as well as of chromosome 1p34, where the genes for histone deacetylase 1 (HDAC1) and transforming growth factor beta receptor interacting protein-1 (TRIP-1) map, are frequent events in hepatocarcinogenesis. This study characterizes the Hep3B cell line in detail at the karyotypic level, using comparative genomic hybridization (CGH), spectral karyotyping (SKY), G-banding and FISH techniques. We have also examined the effects of the histone deacetylase inhibitor trichostatin A (TSA) on members of the IGF-axis, and analysed them with regard to the karyotype. The results show that expression of one member of the IGF-axis, IGFBP-3, is greatly upregulated by treatment of Hep3B cells with TSA. As IGFBP-3 has been shown to induce apoptosis, these results suggest a possible use for histone deacetylase inhibitors and/or IGFBP-3 in the treatment of HCC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Hepatocellular / genetics*
  • Carcinoma, Hepatocellular / therapy
  • Chromosome Banding
  • Chromosome Mapping
  • Eukaryotic Initiation Factor-3
  • Humans
  • Hydroxamic Acids / pharmacology*
  • In Situ Hybridization, Fluorescence
  • Insulin-Like Growth Factor Binding Protein 1 / genetics
  • Insulin-Like Growth Factor Binding Protein 3 / genetics*
  • Insulin-Like Growth Factor II / pharmacology
  • Karyotyping
  • Liver Neoplasms / genetics*
  • Liver Neoplasms / therapy
  • Ploidies
  • Proteins / genetics
  • Receptor, IGF Type 2 / drug effects
  • Ribonucleases / metabolism
  • Tumor Cells, Cultured

Substances

  • Eukaryotic Initiation Factor-3
  • Hydroxamic Acids
  • Insulin-Like Growth Factor Binding Protein 1
  • Insulin-Like Growth Factor Binding Protein 3
  • Proteins
  • Receptor, IGF Type 2
  • EIF3I protein, human
  • trichostatin A
  • Insulin-Like Growth Factor II
  • Ribonucleases